EXtended Therapy in Hepatitis C Genotype 3 Infected Patients
Status:
Terminated
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the effect of 48 vs 24 weeks of treatment with
Peginterferon alfa-2b plus weight-based ribavirin on Sustained Virologic Response (SVR) and
relapse rates in patients infected with genotype 3 chronic hepatitis C (CHC) who do not
achieve a Rapid Virologic Response (RVR) but attain a complete Early Virologic Response
(cEVR).